{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:06Z","timestamp":1792619046241,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pre-existing cardiovascular disease and cardiovascular risk factors are common in patients with COVID-19 and there remain concerns for poorer in-hospital outcomes in this cohort. We aimed to analyse the relationship between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in patients hospitalised with COVID-19 in a prospective, multicentre observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This prospective, multicentre observational study included consecutive patients of age \u226518 in their index hospitalisation with laboratory-proven COVID-19 in Australia. Patients with suspected but not laboratory-proven COVID-19 and patients with no available past medical history were excluded. The primary exposure was pre-existing cardiovascular disease, defined as a composite of coronary artery disease, heart failure or cardiomyopathy, atrial fibrillation or flutter, severe valvular disease, peripheral arterial disease and stroke or transient ischaemic attack. The primary outcome was in-hospital mortality. Secondary outcomes were clinical cardiovascular complications (new onset atrial fibrillation or flutter, high-grade atrioventricular block, sustained ventricular tachycardia, new heart failure or cardiomyopathy, pericarditis, myocarditis or myopericarditis, pulmonary embolism and cardiac arrest) and myocardial injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1,567 patients (mean age 60.7 (\u00b120.5) years and 837 (53.4%) male) were included. Overall, 398 (25.4%) patients had pre-existing cardiovascular disease, 176 patients (11.2%) died, 75 (5.7%) had clinical cardiovascular complications and 345 (37.8%) had myocardial injury. Patients with pre-existing cardiovascular disease had significantly increased in-hospital mortality (aOR: 1.76 95% CI: 1.21\u20132.55, <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and myocardial injury (aOR: 3.27, 95% CI: 2.23\u20134.79, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). There was no significant association between pre-existing cardiovascular disease and in-hospital clinical cardiovascular complications (aOR: 1.10, 95% CI: 0.58\u20132.09, <jats:italic>p<\/jats:italic>\u2009=\u20090.766). On mediation analysis, the indirect effect and Sobel test were significant (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), indicating that the relationship between pre-existing cardiovascular disease and in-hospital mortality was partially mediated by myocardial injury. Apart from age, other cardiovascular risk factors such as diabetes, hypercholesterolemia and hypertension had no significant impact on mortality, clinical cardiovascular complications or myocardial injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pre-existing cardiovascular disease is associated with significantly higher mortality in patients hospitalised with COVID-19. This relationship may be partly explained by increased risk of myocardial injury among patients with pre-existing cardiovascular disease which in turn is a marker associated with higher mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1224886","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T16:34:55Z","timestamp":1688574895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Association between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in hospitalised patients with COVID-19"],"prefix":"10.3389","volume":"10","author":[{"given":"Hari P.","family":"Sritharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwardeep S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Kritharides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinay","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.hlc.2021.08.001","article-title":"Cardiac complications in patients hospitalised with COVID-19 in Australia","volume":"30","author":"Bhatia","year":"2021","journal-title":"Heart Lung Circ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e019671","DOI":"10.1161\/JAHA.120.019671","article-title":"Determinants of influenza vaccine uptake in patients with cardiovascular disease and strategies for improvement","volume":"10","author":"Bhugra","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/qjmed\/hcaa246","article-title":"Defining heart disease risk for death in COVID-19 infection","volume":"113","author":"Li","year":"2020","journal-title":"QJM"},{"key":"B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12872-021-02137-9","article-title":"Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19","volume":"21","author":"O'Gallagher","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13098-020-00565-9","article-title":"Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease","volume":"12","author":"Rastad","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/dom.14124","article-title":"Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis","volume":"22","author":"Singh","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e008942","DOI":"10.1161\/CIRCOUTCOMES.122.008942","article-title":"Relationship between preexisting cardiovascular disease and death and cardiovascular outcomes in critically ill patients with COVID-19","volume":"15","author":"Vasbinder","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5334\/gh.814","article-title":"The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis","volume":"15","author":"Matsushita","year":"2020","journal-title":"Glob Heart"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e045482","DOI":"10.1136\/bmjopen-2020-045482","article-title":"Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study","volume":"11","author":"Collard","year":"2021","journal-title":"BMJ Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5501\/wjv.v11.i1.1","article-title":"Heart failure in COVID-19 patients: critical care experience","volume":"11","author":"John","year":"2022","journal-title":"World J Virol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"901245","DOI":"10.3389\/fcvm.2022.901245","article-title":"Myocardial injury in COVID-19 and its implications in short- and long-term outcomes","volume":"9","author":"Izquierdo-Marquis\u00e1","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.hrtlng.2020.04.019","article-title":"A review of cardiac manifestations and predictors of outcome in patients with COVID-19","volume":"49","author":"Mishra","year":"2020","journal-title":"Heart Lung"},{"key":"B17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.120.050754","article-title":"COVID-19-associated nonocclusive fibrin microthrombi in the heart","volume":"143","author":"Bois","year":"2021","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1001\/jamacardio.2020.3551","article-title":"Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases","volume":"5","author":"Lindner","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5501\/wjv.v11.i5.375","article-title":"Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2","volume":"11","author":"Muthyala","year":"2022","journal-title":"World J Virol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.eclinm.2022.101619","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1224886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T16:34:57Z","timestamp":1688574897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1224886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2023.1224886"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1224886","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"article-number":"1224886"}}